Malignant Ovarian Neoplasm — Trials

Malignant Ovarian Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 684
Recruiting: 385
Ph III recruiting: 46
Growth YoY: +9.8%
Industry share: 37%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.8%
Trials / 1,000 deaths: 53.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (437)

clinicaltrialsPublishedShowing 51–89 of 89 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04553133	PF-07104091 as a Single Agent and in Combination Therapy	active not recruiting	Phase 2	157	PfizerINDUSTRY	4	May 6, 2026	clinicaltrials
NCT05271318	Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.(PROTA)	active not recruiting	Phase 1 / Phase 2	29	TILT Biotherapeutics Ltd.INDUSTRY	2	May 5, 2026